Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Half of people with worse liver function responded well to immunotherapy.
Scientists are preparing to bring DNA-editing tools to the clinic.
A second immunotherapy option is now available for hepatocellular carcinoma.
Immunotherapy combination reduced the risk of death by 36 percent compared with chemotherapy alone.
Median overall survival was 15.9 for the combination versus 11.3 months for chemotherapy alone.
Bavencio or Keytruda plus targeted therapy slowed disease progression in Phase III studies.
Mouse study shows how transplanting patients’ own healthy blood stem cells can curb cancer, opening door to better treatments.
Tecentriq plus chemotherapy delays disease progression or death in people with metastatic triple-negative breast cancer.
Because so few people diagnosed with SCLC survive for even a year despite treatment, an advance in survival rate is quite significant.
Treatment with Opdivo appears to work well for HIV-positive people in small study.
A new area of research is examining the use of checkpoint inhibitors before surgery, a practice known as neoadjuvant therapy.
June is Cancer Immunotherapy Month
How a new technology solved a mystery and honors one man’s legacy
Surprising benefit of aging and the implications for melanoma treatment
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.